Discover AC Immune's Innovations at AD/PD 2025 Event

Exciting Presentations by AC Immune at the Upcoming AD/PD 2025

AC Immune SA (NASDAQ: ACIU), a forefront clinical-stage biopharmaceutical company, is gearing up for significant presentations at the International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2025). Scheduled from April 1 to April 5 in Vienna, Austria, this pivotal event highlights the advancements in their precision medicine pipeline aimed at combating neurodegenerative diseases.

Industry Symposium on Active Immunotherapies

Part of this conference includes an industry symposium that AC Immune will host, showcasing its innovative pipeline for active immunotherapies. This session is set for April 2, providing a platform for industry leaders and experts to discuss tailored prevention strategies in neurodegenerative disease management.

Session Details

The symposium will take place from 8:40 AM to 10:40 AM CET in Hall A. The company’s CEO, Andrea Pfeifer, Ph.D., will deliver opening remarks, highlighting the critical nature of this initiative.

Highlighted Presentations

Several esteemed presenters will contribute, including:

• Dr. Werner Poewe
will discuss disease modification in Parkinson’s disease.
• Dr. Günther Staffler
will share insights on the Phase 2 trial for targeting alpha-synuclein.
• Dr. Philip Scheltens
will focus on precision prevention for Alzheimer’s disease.
• Dr. Lennert Steukers
will present on the first active immunotherapy for Alzheimer’s prevention.
• Dr. Anke Post
will discuss ACI-24.060 and its potential in early Alzheimer’s disease.

Oral Presentations and Emerging Research

Exciting oral presentations will also be featured. Notable developments include the presentation by Dr. Nicolas Preitner, addressing Morphomer® small molecules aimed at Alzheimer’s treatment during the Translational Drug Development and Experimental Models session on April 5.

Virtual On-Demand Content

Moreover, AC Immune will offer virtual on-demand presentations on significant topics, such as Morphomer-antibody drug conjugates and therapeutic small molecules targeting alpha-synuclein aggregation.

Poster Presentations and Collaborations

In addition to oral presentations, posters will detail critical research, including optimal thresholds for clinical trial endpoints in Parkinson’s disease. Collaborations with industry partners will also be showcased, demonstrating antibodies' potential in neurodegenerative therapies.

Research and Development at AC Immune

AC Immune is recognized as a global leader in the precision prevention of neurodegenerative diseases. Their innovative technology platforms, such as SupraAntigen® and Morphomer®, continue to drive breakthroughs in treatment and diagnosis. The company boasts an extensive pipeline featuring both clinical and diagnostic programs, with several candidates in late-stage development.

Future Prospects and Company Vision

By fostering strategic partnerships, AC Immune has secured significant funding aimed at amplifying its proprietary programs and achieving a robust milestone payment structure. The company’s commitment to developing first and best-in-class assets underlines its pivotal role in reshaping approaches to neurodegenerative diseases.

Frequently Asked Questions

What is AC Immune known for?

AC Immune is recognized for pioneering precision therapeutics aimed at neurodegenerative diseases like Alzheimer’s and Parkinson’s.

When is the AD/PD 2025 conference taking place?

The conference will be held from April 1 to April 5, 2025, in Vienna, Austria.

What will AC Immune present at the conference?

They will showcase their advancements in active immunotherapies and participate in an industry symposium featuring multiple presentations.

Who are the key speakers at the symposium?

Key speakers include AC Immune’s CEO Andrea Pfeifer, Dr. Werner Poewe, Dr. Philip Scheltens, and others from leading institutions.

How does AC Immune plan to advance its research?

AC Immune plans to advance its research through strategic partnerships and continued investment in its innovative drug development pipeline.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.